This company has been marked as potentially delisted and may not be actively trading. Adaptimmune Therapeutics (ADAP) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ADAP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Adaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business UpdateMay 22 at 7:47 PM | finanznachrichten.deSixteen new option listings and one option delisting on October 28thOctober 28, 2025 | msn.comAdaptimmune delists from Nasdaq, shifts focus after asset sale to US WorldMedsOctober 28, 2025 | bizjournals.comEvaxion Biotech appoints Tayton-Martin as new CEOOctober 27, 2025 | msn.comLiposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsightOctober 21, 2025 | finance.yahoo.comAdaptimmune stock plunges after announcing Nasdaq delisting plansOctober 20, 2025 | au.investing.comAdaptimmune Therapeutics PLC: Adaptimmune Announces Delisting from NasdaqOctober 20, 2025 | finanznachrichten.deWhy Is Adaptimmune Therapeutics Stock (ADAP) Rising Today?October 10, 2025 | msn.comAdaptimmune Appoints New CFO Christopher HillSeptember 9, 2025 | msn.comAnd just like that, pharma’s breakups reveal pain points in cancer R&DAugust 22, 2025 | finance.yahoo.comAli Behbahani Sells 4,828,206 Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) StockAugust 20, 2025 | insidertrades.comAdaptimmune Therapeutics Stock (ADAP) Rockets 50% on CCO Severance AgreementAugust 18, 2025 | msn.comAdaptimmune Therapeutics (ADAP) Gets a Sell from BarclaysAugust 16, 2025 | theglobeandmail.comAdaptimmune Announces CCO Departure and Severance AgreementAugust 16, 2025 | msn.comAdaptimmune Reports Growth and Strategic Moves in Q2August 14, 2025 | msn.comForm 13G Adaptimmune Therapeutics PLC For: 13 AugustAugust 13, 2025 | investing.comAdaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deAdaptimmune Nicks Higher on Q2 ResultsAugust 13, 2025 | baystreet.caAdaptimmune Announces Termination of Chief Medical OfficerAugust 9, 2025 | theglobeandmail.comY-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&AAugust 6, 2025 | seekingalpha.comAdaptimmune Sells Cell Therapy Assets for $55 MillionJuly 31, 2025 | msn.comHC Wainwright & Co. Downgrades Adaptimmune Therapeutics plc - Depositary Receipt () (ADAP)July 30, 2025 | msn.comA Navy Yard biotech is selling its first-of-its-kind therapy for rare cancer, along with other assetsJuly 29, 2025 | msn.comAdaptimmune Therapeutics stock plunges after selling cell therapy assetsJuly 28, 2025 | au.investing.comA Navy Yard biotech is selling its first-of-its-kind therapy for rare cancer, other assetsJuly 28, 2025 | msn.comAdaptimmune Therapeutics PLC ADR - Barron'sJuly 11, 2025 | barrons.comMizuho Downgrades Adaptimmune Therapeutics plc - Depositary Receipt () (ADAP)June 27, 2025 | msn.comMizuho downgrades Adaptimmune stock on solvency concernsJune 26, 2025 | investing.comAdaptimmune Therapeutics PLC: Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025June 4, 2025 | finanznachrichten.deAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comAdaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...May 14, 2025 | finance.yahoo.comAdaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comA Look Ahead: Adaptimmune Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comAdaptimmune Q1 2025 Earnings PreviewMay 12, 2025 | msn.comAnalysts Conflicted on These Healthcare Names: QuidelOrtho (QDEL) and Enliven Therapeutics (ELVN)May 2, 2025 | theglobeandmail.comAdaptimmune downgraded to Hold from Buy at JonesResearchApril 11, 2025 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Thursday TradingApril 3, 2025 | msn.comWhat Analysts Are Saying About Adaptimmune Therapeutics StockApril 3, 2025 | nasdaq.comAdaptimmune price target lowered to $3 from $3.50 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.com4ADAP : What Analysts Are Saying About Adaptimmune Therapeutics...April 1, 2025 | benzinga.comBarclays Remains a Sell on Adaptimmune Therapeutics (ADAP)March 28, 2025 | markets.businessinsider.comAdaptimmune price target lowered to $1.75 from $3 at GuggenheimMarch 27, 2025 | markets.businessinsider.comAdaptimmune Therapeutics Amends Loan AgreementMarch 26, 2025 | investing.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comAdaptimmune Therapeutics (ADAP) Gets a Buy from ScotiabankMarch 25, 2025 | markets.businessinsider.comEarnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025March 22, 2025 | uk.investing.comAdaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | seekingalpha.comAdaptimmune price target lowered to $1.40 from $3.15 at ScotiabankMarch 22, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (ADAP) Receives a Buy from Mizuho SecuritiesMarch 21, 2025 | markets.businessinsider.comKSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of DirectorsMarch 5, 2025 | markets.businessinsider.com Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼0.000.45▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼11▲ADAP Articles Average Week Get the Latest News and Ratings for ADAP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies DWTX News IMA News ZSQR News FLNA News CING News BYSI News HYFT News TIL News KALA News KZR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
